Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial

Levodopa use in fluctuating Parkinson's disease (PD) is complicated by an inconsistent and prolonged onset to clinical improvement. An orally dissolved carbidopa/levodopa (OD C/L) preparation (Parcopa UCB Pharma) is available in the United States. This offers potential advantages to shorten the...

Full description

Saved in:

Bibliographic Details
Published in:	Movement disorders Vol. 25; no. 16; pp. 2724 - 2727
Main Authors:	Ondo, William G., Shinawi, Lina, Moore, Steven
Format:	Journal Article
Language:	English
Published:	Hoboken Wiley Subscription Services, Inc., A Wiley Company 15-12-2010 Wiley Wiley Subscription Services, Inc
Subjects:	Administration, Oral Aged Antiparkinson Agents - administration & dosage Antiparkinson Agents - therapeutic use Biological and medical sciences Carbidopa - administration & dosage Carbidopa - therapeutic use Cross-Over Studies Double-Blind Method Double-blind studies Drug Combinations Drug toxicity and drugs side effects treatment Female fluctuating Gait Gait - drug effects Humans Latency Levodopa Levodopa - administration & dosage Levodopa - therapeutic use Male Medical sciences Middle Aged Motor Skills - drug effects Movement disorders Neurodegenerative diseases Neurology orally dissolved levodopa Parkinson Disease - drug therapy Parkinson's disease Pharmacology. Drug treatments stride length timed tapping Toxicity: nervous system and muscle Treatment Outcome Nervous system diseases timed tapping Parkinson's disease Carbidopa Tapping Single dose Oral administration fluctuating Parkinson disease Cerebral disorder orally dissolved levodopa stride length Central nervous system disease Placebo Degenerative disease Levodopa Comparative study Extrapyramidal syndrome
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!